Genetic factors associated with response to intravitreal ranibizumab in korean patients with neovascular age-related macular degeneration

Retina

Volumn 34, Issue 2, 2014, Pages 288-297

  Park, Un Chul ^a,b   Shin, Joo Young ^a   Kim, Sang Jin ^a,c   Shin, Eun Soon ^d   Lee, Jong Eun ^d   McCarthy, Linda C ^e   Newcombe, Paul J ^e   Xu, Chun Fang ^e   Chung, Hum ^a   Yu, Hyeong Gon ^a  

^a Seoul National University   (South Korea)

^b National Medical Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d DNA Link Inc   (South Korea)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Age related macular degeneration; Pharmacogenetics; Polymorphism; Ranibizumab

Indexed keywords

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASIAN CONTINENTAL ANCESTRY GROUP; COLORING AGENTS; EYE PROTEINS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GENETIC MARKERS; GENOTYPE; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84895073459     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182979e1e     Document Type: Article

References (43)

1. Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study. AREDS report no. 19. Ophthalmology 2005;112: 533-539.
2. Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of agerelated maculopathy: population-based familial aggregation study. Arch Ophthalmol 1998;116: 1646-1651.
3. Meyers SM, Greene T, Gutman FA. A twin study of age-related macular degeneration. Am J Ophthalmol 1995;120: 757-766.
4. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 2005;102: 7227-7232.
5. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308: 385-389.
6. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308: 419-421.
7. Hadley D, Orlin A, Brown G, et al. Analysis of six genetic risk factors highly associated with AMD in the region surrounding ARMS2 and HTRA1 on chromosome 10, region q26. Invest Ophthalmol Vis Sci 2010;51: 2191-2196.
8. Baird PN, Richardson AJ, Robman LD, et al. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). Hum Mutat 2006;27: 337-342.
9. Lin JM, Wan L, Tsai YY, et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Ophthalmol 2008;145: 1045-1051.
10. Park JH, Lee S, Yu HG, et al. Copy number variation of agerelated macular degeneration relevant genes in Korean population. PLoS One 2012;7:e31243.
11. Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 2008;115: 1019-1025.
12. Feng X, Xiao J, Longville B, et al. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology 2009;116: 1908-1912.
13. Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007;114: 2168-2173.
14. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1419-1431.
15. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1432-1444.
16. Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative agerelated macular degeneration with ranibizumab. Br J Ophthalmol 2009;93: 610-613.
17. Teper SJ, Nowinska A, Pilat J, et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 2010;16: 2598-2604.
18. Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011;52: 4694-4702.
19. Gotoh N, Yamada R, Hiratani H, et al. No association between complement factor H gene polymorphism and exudative agerelated macular degeneration in Japanese. Hum Genet 2006; 120: 139-143.
20. Chen W, Stambolian D, Edwards AO, et al. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A 2010;107: 7401-7406.
21. Zerbib J, Seddon JM, Richard F, et al. rs5888 variant of SCARB1 gene is a possible susceptibility factor for age-related macular degeneration. PLoS One 2009;4:e7341.
22. Lin JM, Wan L, Tsai YY, et al. Pigment epithelium-derived factor gene Met72Thr polymorphism is associated with increased risk of wet age-related macular degeneration. Am J Ophthalmol 2008;145: 716-721.
23. Kopplin LJ, Igo RP Jr, Wang Y, et al. Genome-wide association identifies SKIV2L and MYRIP as protective factors for agerelated macular degeneration. Genes Immun 2010;11: 609-621.
24. Yu Y, Bhangale TR, Fagerness J, et al. Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. Hum Mol Genet 2011;20: 3699-3709.
25. Nakata I, Yamashiro K, Nakanishi H, et al. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J Ophthalmol 2011;55: 435-443.
26. Tian J, Yu W, Qin X, et al. Association of genetic polymorphisms and age-related macular degeneration in Chinese population. Invest Ophthalmol Vis Sci 2012;53: 4262-4269.
27. Janik-Papis K, Zaras M, Krzyzanowska A, et al. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. Exp Mol Pathol 2009;87: 234-238.
28. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39: 367-374.
29. Liu X, Zhao P, Tang S, et al. Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population. Retina 2010;30: 1177-1184.
30. Tsuchihashi T, Mori K, Horie-Inoue K, et al. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology 2011;118: 93-100.
31. Immonen I, Seitsonen S, Tommila P, et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology 2010;117: 103-108.
32. Imai D, Mori K, Horie-Inoue K, et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J Ocul Biol Dis Infor 2010;3: 53-59.
33. Wickremasinghe SS, Xie J, Lim J, et al. Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. Invest Ophthalmol Vis Sci 2011;52: 4072-4079.
34. Kwon OW, Lee FL, Chung H, et al. EXTEND III: efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD. Graefes Arch Clin Exp Ophthalmol 2012;250: 1467-1476.
35. Brantley MA Jr, Edelstein SL, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye (Lond) 2009;23: 626-631.
36. Nischler C, Oberkofler H, Ortner C, et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 2011;89:e344-e349.
37. Orlin A, Hadley D, Chang W, et al. Association between highrisk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 2012;32: 4-9.
38. McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012;96: 208-212.
39. Francis PJ. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2011;109: 115-156.
40. Boltz A, Ruiß M, Jonas JB, et al. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. Ophthalmology 2012;119: 1615-1620.
41. Szeto CC, Chow KM, Poon P, et al. Genetic polymorphism of VEGF: Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney Int 2004; 65: 1947-1955.
42. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002;13: 260-264.
43. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002;51: 1635-1639.